ClinicalTrials.Veeva
Menu

Find clinical trials for Breast Cancer in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Cancer
Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Breast Cancer trials near Milano, Lombardia, ITA:

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

adjuvant chemotherapy regimen in patients with early-stage luminal B breast cancer.The primary endpoint will be to evaluate the fea...

Active, not recruiting
Breast Cancer
Drug: Caelyx®

Phase 2

European Institute of Oncology

Milan, Italy

Breast cancer is the most common form of cancer among women. For patients candidated for adjuvant chemotherapy and endocri...

Active, not recruiting
Breast Cancer
Drug: Anastrozole or Letrozole or Exemestane

Phase 3

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Milano, MI, Italy and 73 other locations

adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast...

Active, not recruiting
Breast Cancer Stage II
Breast Cancer Stage III
Drug: Palbociclib
Drug: Docetaxel / cyclophosphamide

Phase 2

European Organisation for Research and Treatment of Cancer (EORTC)

Monza, Italy and 72 other locations

-positive / HER2-negative breast cancer which has spread beyond the original tumor and/or to other organs.During this stud...

Enrolling
Breast Cancer Recurrent
Drug: Standard endocrine therapy
Drug: Palbociclib 125mg

Phase 3

ETOP IBCSG Partners Foundation

Milan, Italy and 52 other locations

the primary and metastatic (or relapsed) tumor will be collected for central analyses, together with blood, serum and plasma samples. Any s ...

Enrolling
Metastatic Breast Cancer
Procedure: metastatic lesion biopsy
Breast International Group

Milano, Italy and 51 other locations

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...

Active, not recruiting
Metastatic Breast Cancer
Drug: Tucatinib
Drug: Durvalumab

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Milan, Italy and 71 other locations

to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...

Active, not recruiting
Estrogen Receptor Positive Breast Cancer
HER-2 Positive Breast Cancer
Drug: palbociclib
Drug: trastuzumab

Phase 3

Alliance Foundation Trials

Milano, Italy and 117 other locations

This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast...

Active, not recruiting
Breast Cancer
Combination Product: Neoadjuvant combination therapy with olaparib plus durvalumab
Drug: Neoadjuvant Olaparib monotherapy group

Phase 2

AstraZeneca
AstraZeneca

Rozzano, Italy and 43 other locations

This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab
Drug: Trastuzumab deruxtecan

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Milano, Italy and 226 other locations

look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...

Active, not recruiting
HER2-positive Early Breast Cancer
Breast Cancer
Drug: Pertuzumab
Drug: Paclitaxel

Phase 3

AstraZeneca
AstraZeneca

Milano, Italy and 145 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems